{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:39:48Z","timestamp":1772138388147,"version":"3.50.1"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We sought to investigate the tissue specificity of drug sensitivities in large-scale pharmacological studies and compare these associations to those found in drug clinical indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We leveraged the curated cell line response data from PharmacoGx and applied an enrichment algorithm on drug sensitivity values\u2019 area under the drug dose-response curves (AUCs) with and without adjustment for general level of drug sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed tissue specificity in 63% of tested drugs, with 8% of total interactions deemed significant (false discovery rate &amp;lt;0.05). By restricting the drug-tissue interactions to those with AUC\u2009&amp;gt;\u20090.2, we found that in 52% of interactions, the tissue was predictive of drug sensitivity (concordance index\u2009&amp;gt;\u20090.65). When compared with clinical indications, the observed overlap was weak (Matthew correlation coefficient, MCC\u2009=\u20090.0003, P\u2009&amp;gt;\u2009.10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>While drugs exhibit significant tissue specificity in vitro, there is little overlap with clinical indications. This can be attributed to factors such as underlying biological differences between in vitro models and patient tumors, or the inability of tissue-specific drugs to bring additional benefits beyond gold standard treatments during clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our meta-analysis of pan-cancer drug screening datasets indicates that most tested drugs exhibit tissue-specific sensitivities in a large panel of cancer cell lines. However, the observed preclinical results do not translate to the clinical setting. Our results suggest that additional research into showing parallels between preclinical and clinical data is required to increase the translational potential of in vitro drug screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jamia\/ocx062","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T15:26:19Z","timestamp":1499354779000},"page":"158-166","source":"Crossref","is-referenced-by-count":19,"title":["Tissue specificity of in vitro drug sensitivity"],"prefix":"10.1093","volume":"25","author":[{"given":"Fupan","family":"Yao","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ali","family":"Madani Tonekaboni","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaleh","family":"Safikhani","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Smirnov","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehme","family":"El-Hachem","sequence":"additional","affiliation":[{"name":"Integrative Systems Biology, Institut de Recherches Cliniques de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"Department of Medicine, University of Montreal, Montre\u0301al, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Freeman","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkata Satya Kumar","family":"Manem","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Haibe-Kains","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Computer Science, University of Toronto, Toronto, Ontario, Canada"},{"name":"Ontario Institute of Cancer Research, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,7,7]]},"reference":[{"issue":"7216","key":"2020110612452739900_ocx062-B1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","journal-title":"Nature."},{"issue":"7291","key":"2020110612452739900_ocx062-B2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature08987","article-title":"International network of cancer genome projects","volume":"464","author":"International Cancer Genome Consortium","year":"2010","journal-title":"Nature."},{"key":"2020110612452739900_ocx062-B3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12864-015-1687-x","article-title":"Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features","volume":"16","author":"Liu","year":"2015","journal-title":"BMC Genomics."},{"issue":"3","key":"2020110612452739900_ocx062-B4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nmeth.2810","article-title":"Similarity network fusion for aggregating data types on a genomic scale","volume":"11","author":"Wang","year":"2014","journal-title":"Nat Methods."},{"issue":"4","key":"2020110612452739900_ocx062-B5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","article-title":"Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin","volume":"158","author":"Hoadley","year":"2014","journal-title":"Cell."},{"issue":"7","key":"2020110612452739900_ocx062-B6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.cell.2014.05.027","article-title":"From cancer genomics to precision oncology: tissue\u2019s still an issue","volume":"157","author":"Cohen","year":"2014","journal-title":"Cell."},{"issue":"10","key":"2020110612452739900_ocx062-B7","first-page":"691","article-title":"The clinical trial model is up for review: time, expense, and quality of results are at issue, as is the relationship to drug pricing","volume":"39","author":"Barlas","year":"2014","journal-title":"Pharm Therapeutics."},{"issue":"3","key":"2020110612452739900_ocx062-B8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Macarron","year":"2011","journal-title":"Nat Rev Drug Discov."},{"issue":"11","key":"2020110612452739900_ocx062-B9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat Med."},{"issue":"1","key":"2020110612452739900_ocx062-B10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","article-title":"A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds","volume":"167","author":"Bruna","year":"2016","journal-title":"Cell."},{"issue":"7","key":"2020110612452739900_ocx062-B11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djt007","article-title":"The clinical relevance of cancer cell lines","volume":"105","author":"Gillet","year":"2013","journal-title":"J Natl Cancer Inst."},{"key":"2020110612452739900_ocx062-B12","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat Commun."},{"issue":"028159","key":"2020110612452739900_ocx062-B13","first-page":"1","article-title":"Comparing cancer cell lines and tumor samples by genomic profiles","author":"Sinha","year":"2015","journal-title":"bioRxiv."},{"issue":"5","key":"2020110612452739900_ocx062-B14","doi-asserted-by":"crossref","first-page":"575, 577","DOI":"10.2144\/000112598","article-title":"The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?","volume":"43","author":"Hughes","year":"2007","journal-title":"Biotechniques."},{"issue":"7232","key":"2020110612452739900_ocx062-B15","first-page":"935","volume":"457","author":"Identity crisis","year":"2009","journal-title":"Nature."},{"issue":"7547","key":"2020110612452739900_ocx062-B16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature14397","article-title":"A resource for cell line authentication, annotation and quality control","volume":"520","author":"Yu","year":"2015","journal-title":"Nature."},{"issue":"2","key":"2020110612452739900_ocx062-B17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1022908930937","article-title":"False cell lines: the problem and a solution","volume":"39","author":"Masters","year":"2002","journal-title":"Cytotechnology."},{"issue":"7391","key":"2020110612452739900_ocx062-B18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature."},{"issue":"7391","key":"2020110612452739900_ocx062-B19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature."},{"issue":"7603","key":"2020110612452739900_ocx062-B20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature17987","article-title":"Reproducible pharmacogenomic profiling of cancer cell line panels","volume":"533","author":"Haverty","year":"2016","journal-title":"Nature."},{"issue":"11","key":"2020110612452739900_ocx062-B21","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","article-title":"Harnessing connectivity in a large-scale small-molecule sensitivity dataset","volume":"5","author":"Seashore-Ludlow","year":"2015","journal-title":"Cancer Discov."},{"issue":"10","key":"2020110612452739900_ocx062-B22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"2020110612452739900_ocx062-B23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell."},{"issue":"1","key":"2020110612452739900_ocx062-B24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-015-0312-6","article-title":"Drug sensitivity in cancer cell lines is not tissue-specific","volume":"14","author":"Jaeger","year":"2015","journal-title":"Mol Cancer."},{"issue":"4","key":"2020110612452739900_ocx062-B25","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"van de Wetering","year":"2015","journal-title":"Cell."},{"issue":"9","key":"2020110612452739900_ocx062-B26","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/0008-5472.CAN-13-2971","article-title":"Cancer cell lines for drug discovery and development","volume":"74","author":"Wilding","year":"2014","journal-title":"Cancer Res."},{"issue":"7","key":"2020110612452739900_ocx062-B27","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.celrep.2016.07.023","article-title":"Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer","volume":"16","author":"Witkiewicz","year":"2016","journal-title":"Cell Rep."},{"issue":"7480","key":"2020110612452739900_ocx062-B28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature12831","article-title":"Inconsistency in large pharmacogenomic studies","volume":"504","author":"Haibe-Kains","year":"2013","journal-title":"Nature."},{"issue":"7580","key":"2020110612452739900_ocx062-B29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature15736","article-title":"Pharmacogenomic agreement between two cancer cell line data sets","volume":"528","author":"Cancer Cell Line Encyclopedia Consortium, Genomics of Drug Sensitivity in Cancer Consortium","year":"2015","journal-title":"Nature."},{"key":"2020110612452739900_ocx062-B30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.12688\/f1000research.8705.1","article-title":"Assessment of pharmacogenomic agreement","volume":"5","author":"Safikhani","year":"2016","journal-title":"F1000Res."},{"key":"2020110612452739900_ocx062-B31","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.12688\/f1000research.9611.1","article-title":"Revisiting inconsistency in large pharmacogenomic studies","volume":"5","author":"Safikhani","year":"2016","journal-title":"F1000Res."},{"issue":"15","key":"2020110612452739900_ocx062-B32","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1158\/0008-5472.CAN-14-0725","article-title":"Enhancing reproducibility in cancer drug screening: how do we move forward?","volume":"74","author":"Hatzis","year":"2014","journal-title":"Cancer Res."},{"issue":"8","key":"2020110612452739900_ocx062-B33","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/bioinformatics\/btv723","article-title":"PharmacoGx: An R package for analysis of large pharmacogenomic datasets","volume":"32","author":"Smirnov","year":"2016","journal-title":"Bioinformatics."},{"issue":"Database issue","key":"2020110612452739900_ocx062-B34","first-page":"D955","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"2020110612452739900_ocx062-B35","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","article-title":"An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules","volume":"154","author":"Basu","year":"2013","journal-title":"Cell."},{"key":"2020110612452739900_ocx062-B36","unstructured":"Bairoch A . ExPASy-Cellosaurus. Cellosaurus. http:\/\/web.expasy.org\/cellosaurus\/. 2015. Accessed January 26, 2016."},{"key":"2020110612452739900_ocx062-B37","article-title":"SMILES, a Line Notation and Computerized Interpreter for Chemical Structures","author":"Anderson","year":"1987"},{"issue":"Web Server issue","key":"2020110612452739900_ocx062-B38","doi-asserted-by":"crossref","first-page":"W623","DOI":"10.1093\/nar\/gkp456","article-title":"PubChem: a public information system for analyzing bioactivities of small molecules","volume":"37","author":"Wang","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"2020110612452739900_ocx062-B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-2946-5-7","article-title":"InChI-the worldwide chemical structure identifier standard","volume":"5","author":"Heller","year":"2013","journal-title":"J Cheminform."},{"issue":"Database issue","key":"2020110612452739900_ocx062-B40","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"2020110612452739900_ocx062-B41","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nchembio.1337","article-title":"Metrics other than potency reveal systematic variation in responses to cancer drugs","volume":"9","author":"Fallahi-Sichani","year":"2013","journal-title":"Nat Chem Biol."},{"issue":"1","key":"2020110612452739900_ocx062-B42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13059-016-1050-9","article-title":"Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models","volume":"17","author":"Geeleher","year":"2016","journal-title":"Genome Biol."},{"issue":"43","key":"2020110612452739900_ocx062-B43","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"issue":"8","key":"2020110612452739900_ocx062-B44","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1093\/nar\/gkt111","article-title":"Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods","volume":"41","author":"V\u00e4remo","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"2020110612452739900_ocx062-B45","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/j.1420-9101.2005.00917.x","article-title":"Combining probability from independent tests: the weighted Z-method is superior to Fisher\u2019s approach","volume":"18","author":"Whitlock","year":"2005","journal-title":"J Evol Biol."},{"issue":"22","key":"2020110612452739900_ocx062-B46","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1093\/bioinformatics\/btr511","article-title":"Survcomp: an R\/Bioconductor package for performance assessment and comparison of survival models","volume":"27","author":"Schr\u00f6der","year":"2011","journal-title":"Bioinformatics."},{"issue":"1","key":"2020110612452739900_ocx062-B47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol."},{"issue":"4","key":"2020110612452739900_ocx062-B48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med."},{"issue":"Database issue","key":"2020110612452739900_ocx062-B49","doi-asserted-by":"crossref","first-page":"D901","DOI":"10.1093\/nar\/gkm958","article-title":"DrugBank: a knowledgebase for drugs, drug actions and drug targets","volume":"36","author":"Wishart","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"2020110612452739900_ocx062-B50","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1101\/gr.092759.109","article-title":"Circos: an information aesthetic for comparative genomics","volume":"19","author":"Krzywinski","year":"2009","journal-title":"Genome Res."},{"issue":"2","key":"2020110612452739900_ocx062-B51","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0005-2795(75)90109-9","article-title":"Comparison of the predicted and observed secondary structure of T4 phage lysozyme","volume":"405","author":"Matthews","year":"1975","journal-title":"Biochim Biophys Acta."},{"issue":"10","key":"2020110612452739900_ocx062-B52","doi-asserted-by":"crossref","first-page":"e1003285","DOI":"10.1371\/journal.pcbi.1003285","article-title":"Ten simple rules for reproducible computational research","volume":"9","author":"Sandve","year":"2013","journal-title":"PLoS Comput Biol."},{"key":"2020110612452739900_ocx062-B53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13742-015-0087-0","article-title":"Bioboxes: standardised containers for interchangeable bioinformatics software","volume":"4","author":"Belmann","year":"2015","journal-title":"Gigascience."},{"issue":"3","key":"2020110612452739900_ocx062-B54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nbt.3080","article-title":"A comprehensive transcriptional portrait of human cancer cell lines","volume":"33","author":"Klijn","year":"2015","journal-title":"Nat Biotechnol."},{"key":"2020110612452739900_ocx062-B55","doi-asserted-by":"crossref","first-page":"23857","DOI":"10.1038\/srep23857","article-title":"Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine","volume":"6","author":"Gupta","year":"2016","journal-title":"Sci Rep."},{"issue":"9","key":"2020110612452739900_ocx062-B56","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/cncr.28591","article-title":"A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma","volume":"120","author":"Li","year":"2014","journal-title":"Cancer."},{"key":"2020110612452739900_ocx062-B57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ypdi.2011.02.005","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"2011","author":"Tanoue","year":"2011","journal-title":"Yearbook Pulmonary Dis."},{"issue":"5676","key":"2020110612452739900_ocx062-B58","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science."},{"key":"2020110612452739900_ocx062-B59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1634\/theoncologist.9-suppl_3-10","article-title":"Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR\/ErbB-2 inhibitor lapatinib","volume":"9","author":"Burris","year":"2004","journal-title":"Oncologist."},{"issue":"1","key":"2020110612452739900_ocx062-B60","first-page":"149","article-title":"Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate","volume":"4","author":"Din","year":"2008","journal-title":"Ther Clin Risk Manag."},{"key":"2020110612452739900_ocx062-B61","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.gde.2013.12.002","article-title":"The evolving role of cancer cell line\u2013based screens to define the impact of cancer genomes on drug response","volume":"24","author":"Garnett","year":"2014","journal-title":"Curr Opin Genet Dev."},{"issue":"8","key":"2020110612452739900_ocx062-B62","doi-asserted-by":"crossref","first-page":"e0133850","DOI":"10.1371\/journal.pone.0133850","article-title":"Context sensitive modeling of cancer drug sensitivity","volume":"10","author":"Chen","year":"2015","journal-title":"PloS One."},{"issue":"1","key":"2020110612452739900_ocx062-B63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-15-0189","article-title":"Tumor-derived cell lines as molecular models of cancer pharmacogenomics","volume":"14","author":"Goodspeed","year":"2016","journal-title":"Mol Cancer Res."},{"issue":"4","key":"2020110612452739900_ocx062-B64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/pr.109.001461","article-title":"Pharmacogenomic discovery using cell-based models","volume":"61","author":"Welsh","year":"2009","journal-title":"Pharmacol Rev."},{"issue":"46","key":"2020110612452739900_ocx062-B65","doi-asserted-by":"crossref","first-page":"18708","DOI":"10.1073\/pnas.1111840108","article-title":"Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance","volume":"108","author":"Gillet","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"2020110612452739900_ocx062-B66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2014.00040","article-title":"In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies","volume":"4","author":"McDermott","year":"2014","journal-title":"Front Oncol."},{"issue":"2","key":"2020110612452739900_ocx062-B67","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrd1635","article-title":"What\u2019s wrong with our cancer models?","volume":"4","author":"Kamb","year":"2005","journal-title":"Nat Rev Drug Discov."},{"issue":"11","key":"2020110612452739900_ocx062-B68","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2016.175","article-title":"Screening out irrelevant cell-based models of disease","volume":"15","author":"Horvath","year":"2016","journal-title":"Nat Rev Drug Discov."},{"issue":"6","key":"2020110612452739900_ocx062-B69","doi-asserted-by":"crossref","first-page":"e1002476","DOI":"10.1371\/journal.pbio.1002476","article-title":"Standards for cell line authentication and beyond","volume":"14","author":"Almeida","year":"2016","journal-title":"PloS Biol."},{"issue":"6","key":"2020110612452739900_ocx062-B70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nmeth.3403","article-title":"Reproducibility: changing the policies and culture of cell line authentication","volume":"12","author":"Freedman","year":"2015","journal-title":"Nat Methods."},{"key":"2020110612452739900_ocx062-B71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/2041-1480-5-37","article-title":"CLO: The cell line ontology","volume":"5","author":"Sarntivijai","year":"2014","journal-title":"J Biomed Semantics."},{"key":"2020110612452739900_ocx062-B72","first-page":"19","article-title":"The impact of microenvironmental heterogeneity on the evolution of drug resistance in cancer cells","volume":"14","author":"Mumenthaler","year":"2015","journal-title":"Cancer Inform."},{"issue":"19","key":"2020110612452739900_ocx062-B73","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tr\u00e9dan","year":"2007","journal-title":"J Natl Cancer Inst."}],"container-title":["Journal of the American Medical Informatics Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/25\/2\/158\/34150084\/ocx062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/25\/2\/158\/34150084\/ocx062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T04:42:46Z","timestamp":1719290566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamia\/article\/25\/2\/158\/3934669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,7]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,7,7]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jamia\/ocx062","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/085357","asserted-by":"object"}]},"ISSN":["1067-5027","1527-974X"],"issn-type":[{"value":"1067-5027","type":"print"},{"value":"1527-974X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,7,7]]}}}